Modern Wealth Management LLC Acquires Shares of 915 Becton, Dickinson and Company (NYSE:BDX)

Modern Wealth Management LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 915 shares of the medical instruments supplier’s stock, valued at approximately $210,000.

Several other large investors have also made changes to their positions in the company. Taikang Asset Management Hong Kong Co Ltd raised its holdings in Becton, Dickinson and Company by 110.5% during the 4th quarter. Taikang Asset Management Hong Kong Co Ltd now owns 35,050 shares of the medical instruments supplier’s stock worth $7,952,000 after purchasing an additional 18,400 shares during the last quarter. CoreFirst Bank & Trust bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $50,000. Zevenbergen Capital Investments LLC boosted its stake in Becton, Dickinson and Company by 2.4% in the fourth quarter. Zevenbergen Capital Investments LLC now owns 4,980 shares of the medical instruments supplier’s stock valued at $1,130,000 after acquiring an additional 115 shares during the last quarter. ICW Investment Advisors LLC grew its holdings in Becton, Dickinson and Company by 3.3% during the 4th quarter. ICW Investment Advisors LLC now owns 8,901 shares of the medical instruments supplier’s stock worth $2,019,000 after acquiring an additional 284 shares during the period. Finally, Twin City Private Wealth LLC raised its position in shares of Becton, Dickinson and Company by 377.3% during the 4th quarter. Twin City Private Wealth LLC now owns 11,508 shares of the medical instruments supplier’s stock valued at $2,611,000 after acquiring an additional 9,097 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Byrd sold 459 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Down 0.6 %

BDX stock opened at $227.34 on Friday. The business has a 50-day moving average of $231.83 and a 200-day moving average of $231.76. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The stock has a market capitalization of $65.28 billion, a P/E ratio of 37.76, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday. Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Finally, Barclays increased their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.